Companies / Lyell Immunopharma, Inc. / Activity
Activity — Lyell Immunopharma, Inc.
24 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Mar 6, 2026 | ARCH Venture Partners IX, LLC 10% owner | Buy | Common Stock | $12.50M | +488K +52.01% | 1,426,528 5.82% of shares | high |
| Mar 6, 2026 | ARCH Venture Fund XIII, L.P. 10% owner | Buy | Common Stock | $12.50M | +488K +52.01% | 1,426,528 5.82% of shares | high |
| Feb 11, 2026 | Seely Lynn CEO | Sell | Common Stock | $174.4K | -7K -9.12% | 74,266 0.30% of shares | medium |
| Dec 24, 2025 | Bulis Veronica Sanchez Executive | Sell | Common Stock | $43.9K | -1K -12.33% | 8,077 0.03% of shares | low |
| Feb 11, 2026 | Lee Gary K. Executive | Sell | Common Stock | $39.1K | -2K -8.98% | 16,938 0.07% of shares | low |
| Dec 30, 2025 | Bulis Veronica Sanchez Executive | Sell | Common Stock | $30.3K | -936 -11.59% | 7,141 0.03% of shares | low |
| Feb 11, 2026 | Hill Stephen J. Executive | Sell | Common Stock | $28.9K | -1K -6.49% | 17,795 0.07% of shares | low |
| Feb 10, 2026 | Seely Lynn CEO | Sell | Common Stock | $10.1K | -438 -0.53% | 81,721 0.33% of shares | low |
| May 11, 2026 | Seely Lynn CEO | Sell | Common Stock | $7.3K | -388 -0.52% | 73,878 0.30% of shares | low |
| Feb 10, 2026 | Bulis Veronica Sanchez Executive | Sell | Common Stock | $5.9K | -254 -1.60% | 15,637 0.06% of shares | low |
| Feb 10, 2026 | Lee Gary K. Executive | Sell | Common Stock | $3.4K | -147 -0.78% | 18,609 0.08% of shares | low |
| Feb 10, 2026 | Hill Stephen J. Executive | Sell | Common Stock | $2.5K | -109 -0.57% | 19,031 0.08% of shares | low |
| Feb 10, 2026 | Bulis Veronica Sanchez Executive | Grant | Common Stock | $0 | +9K +122.53% | 15,891 0.06% of shares | low |
| Feb 9, 2026 | Lee Gary K. Executive | Grant | Common Stock | $0 | +4K +27.11% | 18,756 0.08% of shares | low |
| Feb 9, 2026 | Hill Stephen J. Executive | Grant | Common Stock | $0 | +4K +26.42% | 19,140 0.08% of shares | low |
| Feb 9, 2026 | Seely Lynn CEO | Grant | Common Stock | $0 | +20K +32.18% | 82,159 0.34% of shares | low |
| Jun 10, 2026 | Brawley Otis W Director | Grant | Option (right to buy) | — | +9K | 9,250 0.04% of shares | low |
| Jun 10, 2026 | Rieflin William Jl Director | Grant | Option (right to buy) | — | +9K | 9,250 0.04% of shares | low |
| Mar 9, 2026 | Shah Smital Executive | Grant | Option (right to buy) | — | +140K | 140,000 0.57% of shares | low |
| Feb 10, 2026 | Shook David Executive | Grant | Option (right to buy) | — | +50K | 50,000 0.20% of shares | low |
| Feb 10, 2026 | Lee Gary K. Executive | Grant | Option (right to buy) | — | +50K | 50,000 0.20% of shares | low |
| Feb 10, 2026 | Hill Stephen J. Executive | Grant | Option (right to buy) | — | +65K | 65,000 0.27% of shares | low |
| Feb 10, 2026 | Meltz Mark A Executive | Grant | Option (right to buy) | — | +50K | 50,000 0.20% of shares | low |
| Feb 10, 2026 | Seely Lynn CEO | Grant | Option (right to buy) | — | +155K | 155,000 0.63% of shares | low |